ClinicalTrials.gg
RecruitingNCT07007065Updated Oct 29, 2026

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

A Phase 3 interventional study of Surabgene Lomparvovec (ABBV-RGX-314) and Ranibizumab Control in Neovascular Age-related Macular Degeneration, sponsored by AbbVie. Recruiting at 138 sites in 17 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 29, 202612 sites added7 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
561
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Macular Degeneration by AbbVie — 3 open to participants now, 6 under way, 3 of them phase 3. Macular Degeneration · AbbVie.

Planned enrollment
5th of 22
561 · median 122
Started
2025
with 1 other
Phase 3
4 of 22
1 open now
Registered
21st of 22
by date

Among the 22 studies in Macular Degeneration by AbbVie, this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 in phase 3, and was the 21st registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 22 studies in Macular Degeneration by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Macular Degeneration by AbbVie, or all of them as a file.
02

Study summary

Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD).

Surabgene Lomparvovec (ABBV-RGX-314) is an investigational gene therapy being developed for the treatment of neovascular age-related macular degeneration (nAMD). Participants will be placed into 1 of 3 groups, called treatment arms. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis of previously treated nAMD will be enrolled. Around 561 participants will be enrolled in the study at approximately 150 sites worldwide.

Participants in groups 1 and 2 will receive a single subretinal dose of ABBV-RGX-314. Participants in group 3 will receive Ranibizumab as needed throughout the study. Ranibizumab will be given as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection), and ABBV-RGX-314 will be given as a subretinal (between the retina and the back of the eye) injection. The Assessment Period begins after randomization (1:1:1) to one of the ABBV-RGX-314 treatment groups or control at Week -2 and lasts up to 5 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular monthly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration

Keywords

  • Neovascular age-related macular degeneration
  • Surabgene Lomparvovec
  • ABBV-RGX-314
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pseudophakic (at least 12 weeks post cataract surgery at Screening Visit 1 [Week -6]) in the study eye.
  • Must have a diagnosis of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye

    --CNV lesion characteristics as assessed by the central reading center: lesion size needs to be less than 10-disc areas (typical disc area = 2.54 mm\^2)

  • Must have received at least 2 intravitreal anti-vascular endothelial growth factor (VEGF) injections in the past 6 months in the study eye prior to Screening Visit 1 (Week -6) and have been responsive (determined by investigator)

Exclusion criteria

Exclusion Criteria:

  • CNV or macular edema in the study eye that is secondary to any causes other than AMD
  • Study eye with nAMD diagnosed > 4 years from Screening Visit 1
  • Any retinal pigment epithelial detachment > 400 μm or any pigment epithelial detachment > 350 μm within the central subfield (central 1 mm) in the study eye at Screening Visit 1 (Week -6), as assessed by the central reading center.
  • Any subretinal hemorrhage in the study eye > 50% of the total lesion area or within the parafovea (3 mm center of the macula), as determined by the central reading center
  • Retinal pigment epithelial tear involving the central subfield (central 1 mm) in the study eye as determined by the central reading center.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
561 participants (estimated)

Study arms

  • Experimental
    Surabgene Lomparvovec (ABBV-RGX-314) Dose 1

    Participants will receive Surabgene Lomparvovec (ABBV-RGX-314) Dose 1 administered via subretinal delivery one time.

    Drug: Surabgene Lomparvovec (ABBV-RGX-314)

  • Experimental
    Surabgene Lomparvovec (ABBV-RGX-314) Dose 2

    Participants will receive Surabgene Lomparvovec (ABBV-RGX-314) Dose 2 administered via subretinal delivery one time.

    Drug: Surabgene Lomparvovec (ABBV-RGX-314)

  • Experimental
    Ranibizumab Control Group

    Ranibizumab administered via intravitreal injection as needed PRN

    Drug: Ranibizumab Control

Interventions

  • DrugSurabgene Lomparvovec (ABBV-RGX-314)

    subretinal injection

    Also known as: Surabgene Lomparvovec

  • DrugRanibizumab Control

    intravitreal injection

06

What researchers measure

Primary outcomes

  1. Annualized intravitreal anti-VEGF injection rate

    To assess the injection burden and the necessity for supplemental anti-VEGF injections over the first year of the study period across the different treatment groups.

    Time frame: Up to Week 54

  2. Number of Participants Experiencing Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 5 years

Secondary outcomes

  1. Change from Baseline in best corrected visual acuity (BCVA)

    BCVA will be measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart

    Time frame: Up to 3 Years

  2. Annualized intravitreal anti-VEGF injection rate

    To evaluate the long-term injection burden and the necessity for supplemental anti-VEGF injections across the different treatment groups.

    Time frame: Up to 3 Years

07

Study locations

138 of 138 sites recruiting
  • Barnet Dulaney Perkins Eye Center - Mesa /ID# 279265
    Mesa, Arizona 85206, United States
    Recruiting
  • American Vision Partners /ID# 264615
    Sun City, Arizona 85351, United States
    Recruiting
  • Retinal Diagnostic Center /ID# 263054
    Campbell, California 95008, United States
    Recruiting
  • The Retina Partners /ID# 263265
    Encino, California 91436, United States
    Recruiting
  • Retina Associates of Southern California /ID# 263056
    Huntington Beach, California 92647, United States
    Recruiting
  • Shiley Eye Institute At Uc San Diego Health /ID# 276682
    La Jolla, California 92093, United States
    Recruiting
  • Northern California Retina Vitreous Associates - Mountain View /ID# 263990
    Mountain View, California 94040-4119, United States
    Recruiting
  • Eye Research Foundation /ID# 277345
    Newport Beach, California 92663, United States
    Recruiting
  • Retina Consultants of San Diego /ID# 264026
    Poway, California 92064-2530, United States
    Recruiting
  • Retina Consultants Of Southern California - Redlands /ID# 276496
    Redlands, California 92374, United States
    Recruiting
  • Kaiser Permanente - Riverside Medical Center /ID# 263253
    Riverside, California 92505, United States
    Recruiting
  • Retinal Consultants - Sacramento - Greenback Lane /ID# 263983
    Sacramento, California 95841, United States
    Recruiting
  • UCSF, Wayne and Gladys Valley Center for Vision /ID# 263058
    San Francisco, California 94143-2510, United States
    Recruiting
  • Orange County Retina Medical Group /ID# 266612
    Santa Ana, California 92705, United States
    Recruiting
  • Retina Consultants of Southern Colorado /ID# 263284
    Colorado Springs, Colorado 80909, United States
    Recruiting
  • Colorado Retina Associates /ID# 263247
    Lakewood, Colorado 80228, United States
    Recruiting
  • Advanced Vision Surgery Center /ID# 264208
    Longmont, Colorado 80503, United States
    Recruiting
  • Advanced Research, LLC /ID# 276526
    Deerfield Beach, Florida 33064-1346, United States
    Recruiting
  • Segal Drug Trials, Inc /ID# 276966
    Delray Beach, Florida 33484, United States
    Recruiting
  • Retina Vitreous Consultants LLP business DBA as Retina Group of Florida /ID# 264631
    Fort Myers, Florida 33917, United States
    Recruiting
  • Florida Retina Institute - Orlando /ID# 263288
    Orlando, Florida 32806, United States
    Recruiting
  • Center for Retina and Macular Disease /ID# 264201
    Winter Haven, Florida 33880, United States
    Recruiting
  • Southeast Retina Center /ID# 263264
    Augusta, Georgia 30909, United States
    Recruiting
  • Vision Medical Research /ID# 277102
    Oak Lawn, Illinois 60453, United States
    Recruiting
  • Springfield Clinic Main Campus /ID# 265202
    Springfield, Illinois 62703-2403, United States
    Recruiting
  • Retina Partners Midwest, P.C. /ID# 264031
    Carmel, Indiana 46032, United States
    Recruiting
  • Wolfe Eye Clinic - West Des Moines /ID# 263270
    West Des Moines, Iowa 50266, United States
    Recruiting
  • Retina Associates - Lenexa /ID# 264607
    Lenexa, Kansas 66215, United States
    Recruiting
  • Maine Eye Center - Marginal Way Campus /ID# 263251
    Portland, Maine 04101, United States
    Recruiting
  • The Retina Care Center /ID# 263263
    Baltimore, Maryland 21209, United States
    Recruiting
  • Retina Specialist /ID# 264633
    Towson, Maryland 21204, United States
    Recruiting
  • Associated Retinal Consultants /ID# 263289
    Royal Oak, Michigan 48073, United States
    Recruiting
  • Retina Consultants of Minnesota (RCM) - Edina Retina Clinic /ID# 279427
    Edina, Minnesota 55435, United States
    Recruiting
  • Mayo Clinic - Minnesota /ID# 263977
    Rochester, Minnesota 55905, United States
    Recruiting
  • Retina Institute - St. Louis /ID# 263985
    St Louis, Missouri 63128, United States
    Recruiting
  • Sierra Eye Associates /ID# 263240
    Reno, Nevada 89502, United States
    Recruiting
  • Monmouth Retina Consultants /ID# 279252
    Little Silver, New Jersey 07739, United States
    Recruiting
  • Cleveland Clinic - Cleveland /ID# 264210
    Cleveland, Ohio 44195, United States
    Recruiting
  • Ohio State Havener Eye Institute - Columbus /ID# 263987
    Columbus, Ohio 43212, United States
    Recruiting
  • Midwest Retina /ID# 263231
    Dublin, Ohio 43016, United States
    Recruiting
  • Erie Retina Research /ID# 263287
    Erie, Pennsylvania 16507, United States
    Recruiting
  • Mid Atlantic Retina - Philadelphia /ID# 263291
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Charleston Neuroscience Institute - Bluffton /ID# 264037
    Bluffton, South Carolina 29910, United States
    Recruiting
  • Charleston Neuroscience Institute - Charleston /ID# 276425
    Charleston, South Carolina 29414, United States
    Recruiting
  • Retina Consultants of South Carolina - Ladson /ID# 277596
    Ladson, South Carolina 29456, United States
    Recruiting
  • Retina Consultants of America /ID# 264038
    Mt. Pleasant, South Carolina 29464, United States
    Recruiting
  • Black Hills Regional Eye Institute /ID# 279258
    Rapid City, South Dakota 57701, United States
    Recruiting
  • Retina Research Institute of Texas /ID# 263233
    Abilene, Texas 79606, United States
    Recruiting
  • Austin Retina Associates - Austin /ID# 266770
    Austin, Texas 78705, United States
    Recruiting
  • Austin Clinical Research, LLC /ID# 263229
    Austin, Texas 78750-2298, United States
    Recruiting
  • Star Retina /ID# 266386
    Burleson, Texas 76028, United States
    Recruiting
  • Retina Consultants of Texas /ID# 263274
    Houston, Texas 77056-3030, United States
    Recruiting
  • Austin Retina Associates - Round Rock /ID# 266776
    Round Rock, Texas 78681, United States
    Recruiting
  • Retina Consultants of Texas - Westover /ID# 264209
    San Antonio, Texas 78251, United States
    Recruiting
  • Rocky Mountain Retina Consultants /ID# 263266
    Murray, Utah 84107, United States
    Recruiting
  • Landesklinikum Mistelbach /ID# 275764
    Mistelbach, Lower Austria 2130, Austria
    Recruiting
  • Medizinische Universitaet Graz /ID# 264511
    Graz, Styria 8010, Austria
    Recruiting
  • Medizinische Universitaet Innsbruck /ID# 264502
    Innsbruck, Tyrol 6020, Austria
    Recruiting
  • Kepler Universitaetsklinikum GmbH /ID# 264493
    Linz, Upper Austria 4020, Austria
    Recruiting
  • Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 264498
    Salzburg, 5020, Austria
    Recruiting
  • UZ Gent /ID# 261300
    Ghent, Oost-Vlaanderen 9000, Belgium
    Recruiting
  • Universitair Ziekenhuis Leuven /ID# 261302
    Leuven, Vlaams-Brabant 3000, Belgium
    Recruiting
  • Specialized Eye Hospital for Active Treatment - Burgas OOD /ID# 275729
    Burgas, 8005, Bulgaria
    Recruiting
  • OCIPSMAED St. Luka /ID# 275727
    Plovdiv, 4002, Bulgaria
    Recruiting
  • Specialized Hospital for Active Treatment of Eye Diseases Zora /ID# 275730
    Sofia, 1784, Bulgaria
    Recruiting
  • Medical Center -Vereya /ID# 275728
    Stara Zagora, 6000, Bulgaria
    Recruiting
  • Retina Centre of Ottawa /ID# 263803
    Ottawa, Ontario K2B 7E9, Canada
    Recruiting
  • Klinicki Bolnicki Centar Zagreb /ID# 276047
    Grad Zagreb, City of Zagreb 10000, Croatia
    Recruiting
  • Klinicka Bolnica Sveti Duh /ID# 275871
    Zagreb, City of Zagreb 10000, Croatia
    Recruiting
  • Specijalna bolnica Svjetlost /ID# 276051
    Zagreb, City of Zagreb 10000, Croatia
    Recruiting
  • Ustredni vojenska nemocnice - Vojenska fakultni nemocnice Praha /ID# 264663
    Prague, Praha 6 169 02, Czechia
    Recruiting
  • Fakultni nemocnice Kralovske Vinohrady /ID# 264660
    Prague, 100 34, Czechia
    Recruiting
  • Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 265073
    Nice, Alpes-Maritimes 06001, France
    Recruiting
  • Hopital Edouard Herriot /ID# 265072
    Lyon, Auvergne-Rhône-Alpes 69003, France
    Recruiting
  • Retine Gallien /ID# 265119
    Bordeaux, Gironde 33000, France
    Recruiting
  • Chu Bordeaux - Hopital Pellegrin /ID# 265123
    Bordeaux, New Aquitaine 33076, France
    Recruiting
  • Centre Hospitalier Universitaire de Nantes - L Hopital l hotel-Dieu /ID# 265077
    Nantes, Pays de la Loire Region 44000, France
    Recruiting
  • Clinique du Val d'Ouest /ID# 265121
    Écully, Rhone 69130, France
    Recruiting
  • Centre Hospitalier Intercommunal de Creteil /ID# 265080
    Créteil, Val-de-Marne 94010, France
    Recruiting
  • Centre Monticelli Paradis d'Ophtalmologie /ID# 265120
    Marseille, 13008, France
    Recruiting
  • Clinique Jules Verne /ID# 265076
    Nantes, 44314, France
    Recruiting
  • Hopital Fondation Adolphe de Rothschild /ID# 265081
    Paris, 75019, France
    Recruiting
  • Centre Hospitalier National d'Ophtalmologie Quinze-Vingts /ID# 265125
    Paris, Île-de-France Region 75571, France
    Recruiting
  • Universitaetsklinikum Freiburg /ID# 275449
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
    Recruiting
  • Universitaetsklinikum Tuebingen /ID# 264283
    Tübingen, Baden-Wurttemberg 72076, Germany
    Recruiting
  • Universitaetsklinikum Ulm /ID# 280004
    Ulm, Baden-Wurttemberg 89081, Germany
    Recruiting
  • LMU Klinikum - Campus Innenstadt /ID# 264285
    Munich, Bavaria 80336, Germany
    Recruiting
  • Universitaetsmedizin Goettingen - Georg-August-Universitaet /ID# 264282
    Göttingen, Lower Saxony 37075, Germany
    Recruiting
  • Medizinische Hochschule Hannover /ID# 264281
    Hanover, Lower Saxony 30625, Germany
    Recruiting
  • Universitaetsklinikum Bonn /ID# 264279
    Bonn, North Rhine-Westphalia 53127, Germany
    Recruiting
  • Universitaetsklinikum Muenster /ID# 280155
    Münster, North Rhine-Westphalia 48149, Germany
    Recruiting
  • Klinikum Ludwigshafen /ID# 275448
    Ludwigshafen am Rhein, Rhineland-Palatinate 67063, Germany
    Recruiting
  • Universitaetsklinikum Schleswig-Holstein - Campus Luebeck /ID# 264284
    Lübeck, Schleswig-Holstein 23538, Germany
    Recruiting
  • Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin /ID# 266366
    Berlin, 12203, Germany
    Recruiting
  • Universitaetsklinikum Hamburg-Eppendorf /ID# 264280
    Hamburg, 20246, Germany
    Recruiting
  • General Hospital of Athens G. Gennimatas /ID# 264243
    Athens, Attica 11527, Greece
    Recruiting
  • University General Hospital Attikon /ID# 264914
    Chaïdári, Attica 12462, Greece
    Recruiting
    • Site Coordinator · Contact+30210 5831336
  • University General Hospital of Heraklion /ID# 264241
    Heraklion, Crete 71500, Greece
    Recruiting
  • University General Hospital of Larissa /ID# 264247
    Larissa, 41110, Greece
    Recruiting
  • Ganglion Orvosi Kozpont /ID# 265210
    Pécs, Baranya 7621, Hungary
    Recruiting

Showing the first 100 of 138 sites across 17 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2033, 88 months after the start.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 88 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 5, 2025
StartActual
Nov 5, 2025
Primary completionEst.
Mar 2033
CompletionEst.
Mar 2033
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added, 7 sites removed
Show 12 added (5 United States, 2 United Kingdom, 1 Italy, 1 France, 1 Germany, 1 Israel, 1 Hungary)
  • Barnet Dulaney Perkins Eye Center - Mesa /ID# 279265 · Mesa, United States
  • Florida Retina Institute - Orlando /ID# 263288 · Orlando, United States
  • Retina Associates - Lenexa /ID# 264607 · Lenexa, United States
  • Azienda Ospedaliero Universitaria delle Marche /ID# 265305 · Ancona, Italy
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 267024 · Newcastle upon Tyne, United Kingdom
  • Black Hills Regional Eye Institute /ID# 279258 · Rapid City, United States
  • Royal Liverpool University Hospital /ID# 265854 · Liverpool, United Kingdom
  • Centre Hospitalier Universitaire de Nantes - L Hopital l hotel-Dieu /ID# 265077 · Nantes, France
  • Universitaetsklinikum Muenster /ID# 280155 · Münster, Germany
  • Retina Partners Midwest, P.C. /ID# 264031 · Carmel, United States
  • Yitzhak Shamir Medical Center /ID# 275679 · Tsrifin, Israel
  • Semmelweis Egyetem /ID# 265473 · Budapest, Hungary
Show 7 removed
  • Barnet Dulaney Perkins Eye Centers /ID# 279265 · Mesa, United States
  • Florida Retina Institute - Lake Mary /ID# 263288 · Lake Mary, United States
  • Azienda Ospedaliero Universitaria delle Marche /ID# 265305 · Ancona, Italy
  • Liverpool University Hospitals NHS Foundation Trust /ID# 265854 · Liverpool, United Kingdom
  • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hotel-Dieu /ID# 265077 · Nantes, France
  • Midwest Eye Institute North Indianapolis /ID# 264031 · Carmel, United States
  • Yitzhak Shamir Medical Center /ID# 275679 · Ẕerifin, Israel
across 5 updates, Oct 8, 2026 – Oct 29, 2026
Show all 5 updates
  1. Oct 29, 2026
    1 site added
    Show site
    • Semmelweis Egyetem /ID# 265473 · Budapest, Hungary
  2. Oct 27, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 United States, 1 Israel)
    • Retina Partners Midwest, P.C. /ID# 264031 · Carmel, United States
    • Yitzhak Shamir Medical Center /ID# 275679 · Tsrifin, Israel
    Show 2 removed
    • Midwest Eye Institute North Indianapolis /ID# 264031 · Carmel, United States
    • Yitzhak Shamir Medical Center /ID# 275679 · Ẕerifin, Israel
  3. Oct 23, 2026
    2 sites added, 1 site removed
    Show 2 added (1 France, 1 Germany)
    • Centre Hospitalier Universitaire de Nantes - L Hopital l hotel-Dieu /ID# 265077 · Nantes, France
    • Universitaetsklinikum Muenster /ID# 280155 · Münster, Germany
    Show 1 removed
    • Centre Hospitalier Universitaire de Nantes - L' Hopital l'hotel-Dieu /ID# 265077 · Nantes, France
  4. Oct 20, 2026
    2 sites added, 1 site removed
    Show 2 added (1 United States, 1 United Kingdom)
    • Black Hills Regional Eye Institute /ID# 279258 · Rapid City, United States
    • Royal Liverpool University Hospital /ID# 265854 · Liverpool, United Kingdom
    Show 1 removed
    • Liverpool University Hospitals NHS Foundation Trust /ID# 265854 · Liverpool, United Kingdom
  5. Oct 8, 2026
    5 sites added, 3 sites removed
    Show 5 added (3 United States, 1 Italy, 1 United Kingdom)
    • Barnet Dulaney Perkins Eye Center - Mesa /ID# 279265 · Mesa, United States
    • Florida Retina Institute - Orlando /ID# 263288 · Orlando, United States
    • Retina Associates - Lenexa /ID# 264607 · Lenexa, United States
    • Azienda Ospedaliero Universitaria delle Marche /ID# 265305 · Ancona, Italy
    • The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 267024 · Newcastle upon Tyne, United Kingdom
    Show 3 removed
    • Barnet Dulaney Perkins Eye Centers /ID# 279265 · Mesa, United States
    • Florida Retina Institute - Lake Mary /ID# 263288 · Lake Mary, United States
    • Azienda Ospedaliero Universitaria delle Marche /ID# 265305 · Ancona, Italy
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07007065
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 5, 2025
Start date
Nov 5, 2025
Primary completion
Mar 2033 (estimated)
Completion
Mar 2033 (estimated)
Last update
Oct 29, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion